Study of maridebart cafraglutide for fatty liver with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new medication (maridebart cafraglutide) to see if it can reduce fat in the liver and help with weight loss. It may be an option for adults with excess liver fat and obesity or overweight who haven't been able to lose weight with diet and exercise alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Have a BMI (body mass index) between 27 and 40
- If you have type 2 diabetes, your blood sugar must be well-controlled (HbA1c 9.5% or lower) and you must be on stable treatment
- Have high levels of fat in your liver (measured by a special scan or MRI)
- Have tried and failed to lose weight with diet and exercise at least once in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term effects of a medication called maridebart cafraglutide for weight management. It is for people who already completed a 72-week study of this drug and want to continue treatment.
This trial tests a medication called maridebart cafraglutide for people with heart failure (where the heart doesn't pump as well as it should) and obesity. The goal is to see if it can help improve symptoms and outcomes.
This study tests a drug called Maridebart Cafraglutide for long-term weight management in people who completed a previous related trial. It looks at how well the drug works and its safety over time.
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
This study tests a new weight-loss medication called maridebart cafraglutide against a placebo in people with moderate to severe obstructive sleep apnea who are not using a CPAP machine. The goal is to find out if weight loss can reduce symptoms like pauses in breathing during sleep.
Hear when a new Overweight or Obesity and Elevated Liver Fat trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.